Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: Current promise and future needs

Current Opinion in Gastroenterology

Volumn 29, Issue 6, 2013, Pages 628-632

  Koenigsknecht, Mark J ^a   Young, Vincent B ^a,b  

^a Division of Infectious Diseases   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bacteriotherapy; Clostridium difficile; faecal microbiota transplantation; recurrent Clostridium difficile infection

Indexed keywords

CLOSTRIDIUM DIFFICILE INFECTION; FAECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FECES MICROFLORA; HUMAN; INTESTINE FLORA; MICROBIAL COLONIZATION; MICROBIAL COMMUNITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; RISK FACTOR; SCREENING; STANDARDIZATION; TRANSPLANTATION;

BIOLOGICAL THERAPY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; INTESTINES; MICROBIOTA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 84886085899     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328365d326     Document Type: Review

References (43)

1. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30:57-66.
2. Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011; 32:387-390.
3. McFee RB, Abdelsayed GG. Clostridium difficile. Dis Mon 2009; 55:439-470.
4. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010; 4:409-416.
5. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55 (Suppl 2):S88-S92.
6. Kelly CP. Current strategies for management of initial Clostridium difficile infection. J Hosp Med 2012; 7 (Suppl 3):S5-S10.
7. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:1027-1034.
8. Bartlett JG. Clostridium difficile: progress and challenges. Ann N Y Acad Sci 2010; 1213:62-69.
9. Limbago BM, Long CM, Thompson AD, et al. Clostridium difficile strains from community-associated infections. J Clin Microbiol 2009; 47:3004-3007.
10. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-1918. (Pubitemid 24177098)
11. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-1775. (Pubitemid 34761404)
12. Brandt LJ. American Journal of Gastroenterology Lecture: intestinal micro-biota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013; 108:177-185.
13. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 2012; 20:313-319.
14. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013; 138:1-11.
15. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunctinthe treatment of pseudomembranous enterocolitis. Surgery 1958; 44:854-859.
16. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012; 107:1755; author reply 1755-1756.
17. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013; 29:79-84.
18. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013; 78:240-249.
19. Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin N Am 2012; 41:781-803.
20. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108:500-508.
21. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002.
22. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colono-scopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:1079-1087.
23. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-415.
24. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:761-767.
25. Kahn SA, Vachon A, Rodriquez D, et al. Patient perceptions of fecal micro-biota transplantation for ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1506-1513.
26. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2012; 9:88-96.
27. Zipursky JS, Sidorsky TI, Freedman CA, et al. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012; 55:1652-1658.
28. Reeves AE, Theriot CM, Bergin IL, et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes 2011; 2:145-158.
29. Hamilton MJ, Weingarden AR, Unno T, et al. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013; 4:125-135.
30. Corthier G, Dubos F, Raibaud P. Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol 1985; 49:250-252. (Pubitemid 15184438)
31. Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun 2012; 80:3786-3794.
32. Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Path 2012; 8:e1002995.
33. Petrof E, Gloor G, Vanner S, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013; 1:3.
34. DiBaise JK, Frank DN, Mathur R. Impact of the gut microbiota on the development of obesity: current concepts. Am J Gastroenterol Suppl 2012; 1:22-27.
35. Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 2012; 107:1452-1459.
36. Dejea C, Wick E, Sears CL. Bacterial oncogenesis in the colon. Future Microbiol 2013; 8:445-460.
37. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011; 108:16050-16055.
38. Collins SM, Surette M, Bercik P. The interplay between the intestinal micro-biota and the brain. Nat Rev Microbiol 2012; 10:735-742.
39. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11:1036-1038.
40. Public Workshop: Fecal Microbiota for Transplantation: Presentations. U.S. Food and Drug Administration. http://www.fda.gov/BiologicsBlood Vaccines/NewsEvents/WorkshopsMeetingsConferences/ucm352636. htm. [Accessed 25 June 2013]
41. Important information about IND requirements for useoffecal microbiota totreat Clostridium difficile infection not responsive to standard therapies. U.S. Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/ NewsEvents/WorkshopsMeetingsConferences/ucm357258.htm. [Accessed 26 June 2013]
42. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human, microbiome. Nature 2012; 486:207-214.
43. McNulty NP, Yatsunenko T, Hsiao A, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med 2011; 3:106ra106.